THE 30-SECOND OVERVIEW
At a glance
Tesamorelin and sermorelin are the two growth hormone-releasing hormone analogues most often compared, and unlike most peptide comparisons this one involves genuinely related molecules. Both act at the GHRH receptor. Both were developed as alternatives to administering growth hormone directly. The differences are in peptide length, in stability, and above all in the depth of the clinical record.
Same receptor, different molecules
Endogenous human GHRH is a 44-amino-acid peptide. Its biological activity resides in the first 29 residues. GHRH(1-29) is the shortest fragment that retains full potency at the receptor.
Sermorelin is that fragment. It is GHRH(1-29), sometimes written as sermorelin acetate, and it was developed on the principle that the shortest active sequence is the most practical to synthesise.
Tesamorelin is the full 44-residue sequence carrying a trans-3-hexenoic acid group at the N-terminus. That modification exists for one reason: dipeptidyl peptidase-4 cleaves native GHRH rapidly at the N-terminal end, and the added group obstructs it. The result is a molecule that persists in circulation substantially longer than the unmodified peptide.
Both bind the same receptor and initiate the same downstream signalling. The difference is how long each survives to do so.
Sermorelin's regulatory history is unusual
Sermorelin held FDA approval as Geref for growth hormone deficiency in children, and it was used diagnostically to assess pituitary function. A GHRH analogue provokes a growth hormone response if the pituitary is capable of one, which distinguishes pituitary from hypothalamic causes.
It was withdrawn from the US market in 2008. The withdrawal was not driven by a safety finding, which is a point frequently confused in secondary sources; it reflected commercial decisions and the availability of recombinant growth hormone. The distinction matters when reading claims about either compound's safety record.
Since withdrawal, sermorelin has been widely compounded, and much of what circulates about its effects derives from compounding-pharmacy practice rather than from trial data. That is a materially weaker evidence source than a registration dataset, and it should be weighted accordingly.
Tesamorelin has the deeper trial record
Tesamorelin ran two phase 3 randomised, placebo-controlled trials in HIV-associated lipodystrophy, enrolling roughly 800 participants combined, and holds current FDA approval for that indication as Egrifta.
The protocol across those trials was 2mg once daily by subcutaneous injection. The primary endpoint was visceral adipose tissue measured by CT, and the trials reported reductions in the region of 15-18% relative to placebo over 26 weeks. Extension work followed participants through 52 weeks and examined what happened when treatment stopped. Visceral fat returned, which is a result worth knowing and one that only a study of that duration could establish.
Sermorelin has no equivalent dataset. Its approval was for a different indication in a different population, decades earlier, under different evidentiary standards, and it no longer holds that approval.
Half-life is the practical difference
Sermorelin's circulating half-life is short, reported in the range of 10 to 20 minutes, because it is an unprotected GHRH fragment meeting DPP-4 in plasma. Its growth hormone response is correspondingly sharp and brief, which is what makes it useful diagnostically: a provocative test wants a clear pulse, not sustained elevation.
Tesamorelin's modification extends this considerably, and the once-daily protocol used in the phase 3 trials follows directly from it. A compound cleared in 15 minutes cannot be dosed once daily and produce a sustained effect; one protected against its primary degradation pathway can.
This is the clearest functional distinction between them, and it explains why the two ended up investigated for different purposes despite acting on the same receptor.
Both depend on a functioning pituitary
Neither compound supplies growth hormone. Both stimulate its release from pituitary somatotrophs, which means both depend on the pituitary being capable of responding.
This is the shared rationale for GHRH analogues over exogenous growth hormone: the release stays subject to normal feedback regulation, including somatostatin inhibition, so the resulting profile is closer to endogenous pulsatility than a direct administration would produce. It is also the shared limitation. Where pituitary capacity is the constraint, neither analogue addresses it.
Both raise IGF-1 through the same pathway, and the tesamorelin trials monitored it as a pharmacodynamic marker rather than as an efficacy endpoint.
What the comparison does not settle
The tesamorelin trials studied one indication in one population. Their effect sizes belong to that context, and the published analyses say so. Extending them to other populations is not supported by the data that produced them.
For sermorelin, the position is different but no stronger: an old approval for a different indication, a market withdrawal, and a subsequent evidence base drawn largely from compounding practice rather than controlled trials. Comparing the two on effect means comparing a modern phase 3 dataset against a much thinner and older record.
Neither compound has published research supporting use outside a controlled setting. Both are supplied for research use only.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370.
2. Falutz, J., Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter trials. Journal of Clinical Endocrinology and Metabolism, 95(9), 4291-4304.
3. Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139-157.
4. Egrifta (tesamorelin for injection) prescribing information. US Food and Drug Administration.
